Skip to main content

Maria Luisa Aznar Ruiz de Alegria

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca
Infectious Diseases
General Hospital
Maria Luisa Aznar Ruiz de Alegria

Maria Luisa Aznar Ruiz de Alegria

Maria Luisa Aznar Ruiz de Alegria

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca
Infectious Diseases
General Hospital

Projects

Incorporació Dr. Israel Molina a la RETICS en Malalties tropicals

IP: Israel Molina Romero
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Antoni Soriano Arandes, Diana Pou Ciruelo, Begoña Treviño Maruri, Juan Espinosa Pereiro, Pau Bosch Nicolau, Nuria Serre Delcor, Fernando M Salvador Velez, Jordi Gómez i Prat, Adrián Sánchez Montalvá, Elena Sulleiro Igual, Ines Mercedes Oliveira Souto
Funding agency: Instituto de Salud Carlos III
Funding: 130542.5
Reference: RD16/0027/0003
Duration: 01/01/2017 - 30/06/2022

Desenvolupament d'un score de risc de cirurgia d'endocarditis: projecte SIES-score (Spanish Infective Endocarditis Surgery Score).

IP: Ignacio Ferreira González
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Nuria Fernández Hidalgo, Aida Ribera Sole, Pilar Tornos Mas, Benito Almirante Gragera
Funding agency: Societat Catalana de Cardiologia
Funding: 3000
Reference: SCC-2012-01
Duration: 01/06/2012 - 30/11/2013

Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas disease (BERENICE) Grant Agreement nº 305937

IP: Israel Molina Romero
Collaborators: Maria Luisa Aznar Ruiz de Alegria, Núria Pérez Picazo, Fernando M Salvador Velez, Tamara Del Rio Higueras, Adrián Sánchez Montalvá, Elena Sulleiro Igual, Olga Sánchez- Maroto Carrizo, Janna Anthonina Slabbekoorn, Esperanza Esteban Serna
Funding agency: EUROPEAN COMMISSION
Funding: 939958.88
Reference: BERENICE_FP7HEALTH2012
Duration: 01/09/2012 - 31/08/2018

Related news

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease

The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.

Related professionals

Jordi Teixidor Serra

Jordi Teixidor Serra

Reconstructive Surgery of the Locomotor System
Read more
Monder Abu-Suboh Abadia

Monder Abu-Suboh Abadia

Physiology and Pathophysiology of the Digestive Tract
Read more
Maria Luiza De Souza Galvao

Maria Luiza De Souza Galvao

Pneumology
Read more
Eva Polverino

Eva Polverino

Main researcher
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.